(Q42928152)

English

Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial

scientific article published on October 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

1 reference

based on heuristic

inferred from title

major depressive disorder

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

author name string

Michael Liebowitz

1

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Ulla Lepola

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Catherine Datto

4

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Dennis Sweitzer

5

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Hans Eriksson

6

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Depression and Anxiety

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

964-976

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

21 January 2018

Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

21 January 2018

The assessment of anxiety states by rating

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

21 January 2018

Movement Disorders Associated With the Serotonin Selective Reuptake Inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

21 January 2018

Relapse of depression in primary care. Rate and clinical predictors.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled st

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

A rating scale for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

Sertraline in the prevention of depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

EPS profiles: the atypical antipsychotics are not all the same

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

Extrapyramidal side-effects of antipsychotics in a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.20740

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DA.20740

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42928152&oldid=1973920449"